ERBB2 and gastric cancer: The Chinese Society of Clinical Oncology (CSCO) guidelines (Wang et al., 2024) and National Comprehensive Cancer Network (NCCN) guidelines (National Comprehensive Cancer Network, 2024) recommend ramucirumab plus paclitaxel as the preferred second-line treatment for advanced Human Epidermal Growth Factor Receptor 2 (HER2)-negative GC.